Premier Alternatives

Elixirgen Therapeutics

Baltimore, MD · Founded 2012 · Privately Held (backing)

Developer of stem cell therapies designed for treating syndrome and Alzheimer's diseases through regenerative and rejuvenating medicines. Elixirgen Therapeutics is based in Baltimore, MD and was founded in 2012. Its last reported valuation was $67 million in Nov 2023. It has raised $29.1 million across 8 recorded rounds; the latest was a $4 million seed round in Oct 2025.

Last reported valuation
$67.0M
Nov 2026
Priced at
—
Total raised
$29.1M
Last round
Seed Round
Oct 2025
What is Elixirgen Therapeutics worth?
$67.0Mlast reported valuation · Nov 2026

Elixirgen Therapeutics's last reported valuation, Nov 2023. Nothing priced has surfaced since.

Valuation timeline

0 priced rounds · 60 daily marks since · Sep 2026 – Nov 2026
▮▮
Markrounds hold their value until the next priced eventMark, today
log scale
Post-money values unlock with a free Private Market View account.Unlock the axis

Membership and data by Private Market View

Elixirgen Therapeutics funding history

8 rounds
DateRoundRaisedPost-money
Oct 2025Seed Round$4.0M▮
Mar 2025Seed Round$3.6M▮
Jan 2025Seed Round$600K▮
Nov 2023Early Stage VC$7.0M▮
Sep 2022Debt$5.0M▮
Feb 2021Seed Round$4.2M▮
+ 2 earlier rounds · a free Private Market View account shows the full history
Unlock post-money valuations

Membership and data by Private Market View

Elixirgen Therapeutics valuation

Elixirgen Therapeutics's last reported valuation was $67 million in Nov 2023. No priced round, secondary trade or fund mark has surfaced since.

How much has Elixirgen Therapeutics raised?

Elixirgen Therapeutics has raised $29.1 million across 8 recorded rounds since 2018. The largest was a $7 million early-stage round in Nov 2023; the most recent was a $4 million seed round in Oct 2025.

Elixirgen Therapeutics has filed 9 Form Ds with the SEC since 2018, most recently in Nov 2025 ($4 million sold to 1 investor).

How Elixirgen Therapeutics's valuation is determined

Private company valuations aren’t quoted on an exchange — they’re established in moments: a priced funding round sets a post-money valuation, secondary trades print at a price per share, and SEC-registered funds holding the stock report fair-value marks in their N-PORT filings.

For Elixirgen Therapeutics, the most current credible signal sets the number and the older ones confirm it: a live secondary-market price first, then three or more recent prints, then institutional fund marks, and otherwise the last priced round, which never decays. The valuation is the last round’s post-money moved by the price change since that round, so no share count is assumed. Today it is set by last reported valuation. Question about this number? Full methodology →

Frequently asked about Elixirgen Therapeutics

What is Elixirgen Therapeutics worth?
Elixirgen Therapeutics is valued at $67.0M as of Nov 2026. Elixirgen Therapeutics's last reported valuation, Nov 2023. Nothing priced has surfaced since.
How much has Elixirgen Therapeutics raised?
Elixirgen Therapeutics has raised $29.1M in total funding across 8 recorded rounds.
When did Elixirgen Therapeutics last raise?
Elixirgen Therapeutics last raised in Oct 2025 (Seed Round), raising $4.0M.